TP53 and neoplasm: A single-nucleotide polymorphism at position 309 (SNP309) in MDM2 promoter generates a binding site for the transcription factor SP1, increases MDM2 expression, and leads to mitigated p53 activity and acceleration of tumor development in humans (Bond et al., 2004).